Combretastatin A4 Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 397

Clinical Trials

Multiple clinical trials have evaluated Combretastatin A4 across Phase I, Phase II, and Phase III for oncology and ophthalmology indications, sponsored by academic institutions such as Johns Hopkins University alongside industry entities like Mateon Therapeutics. Investigated conditions include solid tumors, head and neck cancer, anaplastic thyroid cancer, age-related macular degeneration, choroidal neovascularization, and degenerative myopia. While several trials assessing safety, tolerability, and combination regimens were successfully completed, certain Phase II and Phase III trials in thyroid cancer were ultimately terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00507429	TERMINATED	Anaplastic Thyroid Cancer	Mateon Therapeutics	2007-08	PHASE2; PHASE3
NCT00653939	COMPLETED	Tumors	Mateon Therapeutics	2008-03	PHASE2
NCT00113438	COMPLETED	Cancer; Tumor	Mateon Therapeutics	2005-03	PHASE2
NCT00060242	COMPLETED	Head and Neck Cancer	Case Comprehensive Cancer Center	2003-02	PHASE2
NCT00077103	TERMINATED	Head and Neck Cancer	Case Comprehensive Cancer Center	2003-11	PHASE1; PHASE2
NCT00395434	COMPLETED	Tumors	Mateon Therapeutics	2006-09	PHASE1
NCT01423149	COMPLETED	Choroidal Neovascularization; Myopia, Degenerative	Mateon Therapeutics	2005-03	PHASE2
NCT01570790	COMPLETED	Combretastatin A4 Phosphate; Age-related Macular Degeneration; AMD; CNV; Choroidal Neovascularization	Johns Hopkins University	2003-05	PHASE1; PHASE2
NCT00003698	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	University of Glasgow	1998-07	PHASE1

(data from https://clinicaltrials.gov, updated on 2014-06-09)

Check the Combretastatin A4 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Combretastatin A4 selectively binds to β-tubulin with a Kd of 0.4 μM, inhibiting microtubule polymerization and destabilizing the dynamic endothelial cytoskeleton. This acute cytoskeletal disruption triggers vascular shutdown and tumor necrosis, underlying its therapeutic investigation in solid tumors, anaplastic thyroid cancer, and choroidal neovascularization.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).